The global respiratory diagnostics market, valued at US$ 5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$ ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.